Vivos Therapeutics(VVOS) - 2023 Q4 - Annual Results

Exhibit 99.1 Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos' Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses Declined 27% Due to Success of Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., March 28, 2024 – Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commerc ...